The induction of ISGs following i.v. infusion of CVA21 implies an interferon response, and IFN-α2 has known cytotoxic potential against both AML and MM, with multiple IFN-α-based clinical trials having been completed [40, 41]. This evidence concerns the gene IFNA2 and acute myeloid leukemia.